Opiant Pharmaceuticals (OPNT) Getting Somewhat Favorable Media Coverage, Study Finds
News coverage about Opiant Pharmaceuticals (NASDAQ:OPNT) has trended somewhat positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Opiant Pharmaceuticals earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave news stories about the technology company an impact score of 46.6118173419188 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
- FY2018 EPS Estimates for Opiant Pharmaceuticals, Inc. (OPNT) Decreased by Analyst (americanbankingnews.com)
- Analysts Issue Forecasts for Opiant Pharmaceuticals, Inc.’s Q1 2018 Earnings (OPNT) (americanbankingnews.com)
- Opiant Pharmaceuticals, Inc. :OPNT-US: Earnings Analysis: Q4, 2017 By the Numbers : October 17, 2017 (finance.yahoo.com)
- BRIEF-Opiant Pharmaceuticals files for mixed shelf of upto $150 mln (OPNT) (markets.businessinsider.com)
- Opiant Pharmaceuticals : Reports Fiscal Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update (4-traders.com)
Shares of Opiant Pharmaceuticals (NASDAQ OPNT) opened at 34.775 on Friday. Opiant Pharmaceuticals has a one year low of $5.00 and a one year high of $51.90. The stock has a market capitalization of $70.45 million, a price-to-earnings ratio of 13.078 and a beta of -0.97. The company has a 50-day moving average of $37.20 and a 200 day moving average of $16.77.
Opiant Pharmaceuticals (NASDAQ:OPNT) last posted its quarterly earnings data on Friday, October 13th. The technology company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.70. The business had revenue of $3.77 million for the quarter. Opiant Pharmaceuticals had a return on equity of 278.86% and a net margin of 35.68%. Equities research analysts forecast that Opiant Pharmaceuticals will post $0.50 earnings per share for the current fiscal year.
OPNT has been the topic of several analyst reports. ValuEngine upgraded Opiant Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday, September 12th. TheStreet upgraded Opiant Pharmaceuticals from a “c+” rating to a “b” rating in a report on Monday.
ILLEGAL ACTIVITY NOTICE: “Opiant Pharmaceuticals (OPNT) Getting Somewhat Favorable Media Coverage, Study Finds” was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another site, it was illegally copied and republished in violation of international copyright and trademark laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/10/20/opiant-pharmaceuticals-opnt-getting-somewhat-favorable-media-coverage-study-finds.html.
Opiant Pharmaceuticals Company Profile
Opiant Pharmaceuticals, Inc, formerly Lightlake Therapeutics, Inc, is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA).
Receive News & Stock Ratings for Opiant Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.